GlassScriptPhysician profile
Alonzo Burba
NPI 1790754133
$1,832.54
in general payments reported to CMS, 2019-2025
16 companies · $150 in 2025
The $150 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $405 · 2020: $242 · 2021: $748 · 2022: $168 · 2023: $13.81 · 2024: $105 · 2025: $150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $150 · Food and Beverage: $119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $150.00 |
| Food and Beverage | $119.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $465.35 | 2019-2022 | |
| Kyowa Kirin, INC. | $224.08 | 2020-2024 | Nourianz |
| Abbvie INC. | $199.09 | 2021-2023 | Qulipta |
| Biogen, INC. | $150.00 | 2025 | Tysabri |
| Upsher-Smith Laboratories LLC | $143.18 | 2020-2022 | |
| Allergan, INC. | $122.91 | 2020 | |
| Emd Serono, INC. | $122.90 | 2019 | |
| Alexion Pharmaceuticals, INC. | $99.79 | 2019 | |
| Lundbeck LLC | $89.03 | 2021 | |
| Supernus Pharmaceuticals, INC. | $64.90 | 2020 | |
| Amneal Pharmaceuticals LLC | $63.19 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $27.77 | 2021 | |
| Lilly USA, LLC | $21.05 | 2022 | |
| Novartis Pharmaceuticals Corporation | $14.90 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.24 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impel Pharmaceuticals INC. | $12.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alonzo Burba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.